Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Nasacort in Chronic Non Allergic and Non Infectious Rhinitis in Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patient presenting with Chronic Non Allergic and Non Infectious Rhinitis capable of benefiting from corticosteroid therapy administered via the nasal route.~* patient with chronic rhinitis of minimum duration 12 weeks, whether or not consecutive, per year.~* patient with Non Allergic Rhinitis confirmed by negative phadiatop test.~* patient presenting a mean global score for the 5 symptoms \>= 5 (nasal obstruction, rhinorrhea, disturbance of sense of smell, sneezing, facial heaviness), or mean score for the 3 main symptoms (nasal obstruction, rhinorrhea, disturbance of sense of smell) \>= 5 (mean for 7 days prior to visit V0).~* patient presenting an inflammation score at anterior rhinoscopy or nasal endoscopy \>= 4.~Exclusion Criteria:~* patient presenting a nasal polyp~* patient presenting a severe septal deviation which would interfere with insertion of the nasal spray~* patient presenting a nasal cavity tumor~* patient presenting a sinus infection~* patient presenting a history of endonasal surgery~* patient presenting a chronic rhinitis of extrinsic origin (drug-related or food-related rhinitis) or intrinsic origin (hormonal rhinitis, positional rhinitis,atrophic rhinitis, ...)~* patient on a program of intensive sports training~* patient presenting with : cystic fibrosis, pulmonary mycosis, necrotising vascularitis, immotile cilia syndrome, ....~* patient presenting with known immunosuppression, lymphoma~* patient presenting with a known cardiovascular, neurological or other medically significant illness~* patient presenting with known renal failure, with known glaucoma, with known drug addiction~* current antibiotic therapy~* corticosteroids administered in the two months prior to admission~* patient presenting problems of haemostasis (epistaxis), ophthalmic and/or oro-bucco-nasal herpetic infection.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).